Hormone Optimization through Functional Medicine Strategies

Hormone Optimization through Functional Medicine and Chiropractic

Abstract

As Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I share a clear, first-person roadmap for delivering safe, effective hormone optimization that integrates functional medicine and integrative chiropractic care. I explain how I time labs for faster, more precise decisions; how I use structured intake, informed consent, and one-time dosing calculations; and how I co-manage thyroid autoimmunity, metabolic inflammation, and sex hormone dynamics with rehabilitation strategies that modulate autonomic tone and pain. I also present detailed, evidence-based techniques for subcutaneous pellet implantation, including plane selection, incision orientation, linear-tract placement for improved pharmacokinetics, sutureless closure, compression dressings, and post-procedure movement hygiene. Two case narratives (postmenopausal female with thyroid autoimmunity and middle-aged male with low free testosterone and low SHBG) illustrate how physiology and advanced testing inform individualized care.

---

Introduction: My Integrative, Evidence-Based Framework

I practice with a simple aim: deliver safe, effective, and transparent hormone care that aligns physiology with behavior, movement, and modern evidence. I build each plan around:

• Precise lab timing and follow-up scheduling to capture actionable physiology.
• Structured intake and a one-time dose calculator to set a safe starting point.
• Comprehensive, signed informed consent that educates and protects.
• Integrative chiropractic care to modulate autonomic tone, improve biomechanics, reduce pain, and enhance endocrine efficiency.
• Provide clear patient communications through QR-enabled videos, PDFs, and reminders to reduce anxiety and missed steps.

In my clinics, this framework reduces adverse events, shortens time-to-benefit, and improves adherence across hormone therapy, thyroid support, metabolic risk reduction, and procedural follow-up (Bhasin et al., 2018; Jonklaas et al., 2014; Miller et al., 2022; Whitehead & Holyoak, 2020).

Hormone Lab Timing: Why Minutes and Weeks Matter

I specify lab windows to see the biology in motion and course-correct promptly:

• Immediate checks when relevant: Around 45 minutes after selected agents, I may assess acute pharmacodynamic response to verify absorption and receptor sensitivity, especially when early subjective changes are critical to decision-making (Goodman & Gilman, 2022).
• One-week post-intervention labs: I often check early steady-state trends at approximately one week to prevent avoidable maladaptation when symptoms persist. I defer long gaps if patients are struggling, because endocrinology is dynamic and time-sensitive (Cohen et al., 2023).

Physiological logic

• Receptor kinetics, carrier proteins such as sex hormone-binding globulin (SHBG), and conversion enzymes such as deiodinases (T4→T3) respond quickly to inflammation, nutrient status, circadian rhythm, and autonomic tone (Fliers et al., 2010; Mullur et al., 2014; Jonklaas et al., 2014). Short-interval checks followed by broader intervals let me triage whether issues arise from absorption, conversion, binding, or receptor response—and intervene before deficits compound.

Patient Communication Systems That Improve Adherence

Patients forget details when stressed. To eliminate confusion:

• I hand out 4×6 cards with QR codes linking to short, plain-language video instructions.
• I provide printable PDFs for redundancy.
• I automate reminders at set intervals to prompt follow-up scheduling and lab completion.

This multimodal approach aligns with evidence that video education, along with written materials and reminders, improves adherence and reduces anxiety in chronic and post-procedural care (Miller et al., 2022; Whitehead & Holyoak, 2020).

Informed Consent Documentation That Educates and Protects

My consent process reads like a concise white paper—clear, respectful, and comprehensive:

• I explain FDA context, including off-label use in hormone care and the regulatory status of pellet ingredients and compounding processes (FDA, 2020).
• I review risks, benefits, alternatives, and the role of shared decision-making.
• I clarify lab variability and the importance of clinical context.
• I archive signed consent and separately signed post-procedure instructions. These records protect patient rights and ensure our workflow is board-ready.

Dosing Strategy: Why I Use the Calculator Once

I use a vetted, quantitative dose calculator exactly once—after I have completed baseline labs and a thorough intake. That provides a safe, individualized starting point. From there, I titrate based on symptoms, side effects, and targeted follow-ups rather than recalcifying the starting model (Carvalho & Rocha, 2023).

• Biology is nonlinear; repeated recalculations often chase diurnal and assay noise.
• Conservative titration stabilizes homeostatic feedback loops across the HPA and HPG axes and reduces adverse events.

Female Intake Essentials: Duration of Estrogen Deprivation and Progesterone Balance

For women, I prioritize:

• Duration of estrogen deprivation: A 20–25-year estrogen gap requires cautious initiation; receptor expression and hepatic metabolism change with long deprivation (Lobo, 2017; Manson et al., 2013).
• Current cycles and hormone medications: Active menses, oral contraceptives, or SERMs alter SHBG, hepatic enzymes, and receptor dynamics (Rosner, 2010).
• Symptom clusters: Night sweats, sleep disturbance, vasomotor instability, and mood shifts inform delivery form and timing (Thurston et al., 2020).

Why it matters

• Estrogen modulates endothelial nitric oxide, thermoregulation, serotonin, and bone turnover; abrupt, high-dose starts after long deprivation can cause palpitations, edema, and mood symptoms. Progesterone supports GABAergic tone; balancing it avoids sleep and anxiety flares (Schiller et al., 2014).

Male Intake Essentials: Free Testosterone, SHBG, and Cardiometabolic Context

For men, I focus on:

• Free testosterone alongside total T to capture bioactivity and SHBG effects.
• Sleep, mood, libido, morning energy, and exercise recovery as functional markers.
• Insulin resistance, inflammation, and hepatic status to contextualize androgen response and risk (Kelly & Jones, 2015; Morales et al., 2021).

Why it matters

• Androgen therapy modulates muscle protein synthesis, erythropoiesis, and mood; dosing must anticipate hematocrit shifts and vascular risk. Free T avoids misinterpretation when SHBG is aberrant (Bhasin et al., 2018).

Required Data: The Structured Profile That Improves Outcomes

I mark critical intake fields as required:

• Birth year (risk strata), diagnoses, meds, lifestyle patterns, and symptom checklists.
• Structured data improves algorithmic transparency, reproducibility, and titration safety.

Lab Strategy Anchors

I rely on cornerstone panels:

• A1C, fasting insulin, and HOMA-IR are proxies for mapping insulin resistance (Petry & Wade, 2020).
• ApoB with lipids to calibrate atherogenic risk when replenishing sex steroids (Sniderman et al., 2019).
• Thyroid (TSH, free T4/T3), vitamin D3, hematocrit/hemoglobin, sex steroids, SHBG, and FSH/LH to localize axis status and guide safe initiation (Holick, 2007; Jonklaas et al., 2014; Bhasin et al., 2018).
• I treat labs as anchors—then I titrate based on symptoms, safety markers, and follow-up cadence to avoid over-fitting to transient variation.

Integrative Chiropractic Care: The Neuroendocrine-Musculoskeletal Link

Integrative chiropractic is foundational in my endocrine work. With adjustments, soft-tissue techniques, and graded movement, I aim to:

• Reduce nociception and normalize autonomic balance, increasing parasympathetic tone and easing sympathetic overdrive linked to cortisol excess, impaired T4→T3 conversion, and reduced SHBG synthesis (Chrousos, 2009; Mullur et al., 2014).
• Improve heart rate variability, sleep quality, and movement capacity—key drivers of insulin sensitivity and adipokine balance (Brolinson et al., 2012; Haavik & Murphy, 2012; Pedersen & Febbraio, 2012).
• Coordinate load progressions so patients fully leverage hormonal gains.

In my practice, I observe smoother hormonal adaptations, fewer flares, and better adherence when we align biomechanics and autonomic tone with endocrine dosing.

Case 1: Postmenopausal Female with Thyroid Autoimmunity

A 59-year-old, 10 years postmenopausal, presents with weight gain, constipation, low libido, depressed mood, and fatigue.

Key findings

• Elevated TSH, low free T3, low total T4, and high TPO antibodies suggest Hashimoto’s thyroiditis (Effraimidis & Wiersinga, 2014).
• Borderline B12; vitamin D sufficient on pediatric-level dosing; ferritin adequate.

Plan and rationale

• Thyroid therapy: In symptomatic Hashimoto’s with low free T3, I may consider an LT4 + LT3 combination in select cases, with careful monitoring of cardiac, bone, and symptom status (Jonklaas et al., 2014; Grozinsky-Glasberg et al., 2006).
• Autoimmunity and gut: Address dysbiosis, constipation, and micronutrient deficiencies; selenium may reduce TPO antibodies; zinc supports T3 receptor function (Wang et al., 2018; Toulis et al., 2010).
• Nutrients: Increase vitamin D3 and pair with vitamin K2 (MK-7) to support bone and calcium handling; ensure magnesium sufficiency (Holick, 2007; Rosen et al., 2012).
• Integrative chiropractic: Improve thoracic mobility, rib mechanics, and diaphragmatic efficiency to enhance vagal tone and reduce sympathetic bottlenecks that impair conversion. As pain decreases and breathing improves, exercise returns, supporting insulin sensitivity and weight loss.

Hormone nuance

• Menopausal therapy respects oncology history; if breast cancer risk exists, I individualize and consider non-hormonal or local options in accordance with NAMS guidance and oncology input (NAMS, 2023).

Case 2: Middle-Aged Male with Low Free T and Low SHBG

A 59-year-old male reports fatigue, low motivation, trunk adiposity, and musculoskeletal pain.

Key findings

• Borderline total T (~300 ng/dL) with markedly low free T; SHBG is low—often a signature of insulin resistance and fatty liver risk (Selva et al., 2009).
• Inflammatory markers (e.g., CRP) are elevated; cardiometabolic risk is suspected; advanced lipids and apolipoproteins are warranted (Arnett et al., 2019; Grundy et al., 2019).

Plan and rationale

• Sequence before testosterone: Treat sleep apnea, optimize thyroid function, and target insulin resistance and fatty liver; these suppress testosterone and compound the risk (Corona et al., 2014).
• Exercise: Program progressive resistance training and interval work to boost muscle mass, insulin sensitivity, and endogenous T (Kraemer & Ratamess, 2005).
• Integrative chiropractic: Decrease lumbar-thoracic-shoulder pain; restore hip hinge, thoracic extension, scapular mechanics to lift training quality and endocrine response.
• Nutrition: Anti-inflammatory patterns, increased omega-3s, and reduced refined carbs to improve SHBG and free T bioavailability (Maki et al., 2009).
• If androgen therapy proceeds, I follow guideline-based monitoring for hematocrit, blood pressure, mood, and prostate parameters (Bhasin et al., 2018; Morgentaler et al., 2015).

Why Activity Changes Dose Tissue Demand and Receptor Biology

Two patients with the same serum level can require different doses. Higher activity improves blood flow, receptor density, and mitochondrial biogenesis, changing tissue utilization (Hawley et al., 2014). By reducing pain and improving mobility through chiropractic care, I often achieve better function at lower doses, minimizing exposure while preserving outcomes.

Advanced Cardiometabolic Profiling Beyond Cholesterol

I track:

• A1C, fasting insulin, and HOMA-IR for insulin resistance.
• CRP and inflammatory markers to guide anti-inflammatory therapeutics.
• Liver enzymes and imaging (when indicated) for fatty liver. Broadened reference ranges can mask dysfunction, so I interpret in the clinical context (Loria et al., 2013).

Gut Health, Constipation, and Hormone Efficacy

Constipation and dysbiosis can:

• Impair micronutrient absorption.
• Increase beta-glucuronidase activity, amplifying estrogen recirculation.

I address fiber, hydration, magnesium, motility, and microbes; stabilizing gut function can reduce thyroid autoimmunity and improve systemic inflammation, thereby amplifying the benefits of hormone therapy (Dimidi et al., 2017; Marietta et al., 2019).

Pellet Implantation Technique: Tissue-Sparing Methods and Stable Kinetics

When pellets are indicated, I prioritize a minimally disruptive, evidence-informed approach:

• Incision orientation: I align the incision parallel to Langer’s lines (belt line) to reduce dehiscence and scarring (Langer, 1861; Atiyeh et al., 2005).
• Plane selection: I target deep subcutaneous adipose tissue above the muscle fascia, rather than the superficial dermis or superficial fascia, to reduce irritation, bleeding, and extrusion.
• Linear-tract placement: Rather than creating a large cavity, I develop a gently dilated linear tract and distribute pellets in a line to increase tissue contact surface area and promote uniform diffusion (Hsu et al., 2016; Dellas et al., 2021).
• Anesthesia strategy: I anesthetize both entry and tract (proximal and distal) and advance the cannula at roughly 60 degrees to the skin plane to reach deep fat without penetrating muscle. Dual-track anesthesia reduces nociceptive responses and sympathetic vasoconstriction, thereby reducing bruising (Anderson et al., 2019).

Why surface area and fascial architecture matter

• A larger pellet-tissue interface stabilizes concentration gradients (per Fick’s law), reducing peaks and troughs and discouraging fibrotic encapsulation that blunts release (Hsu et al., 2016).
• Respecting fascial continuity anchors pellets and reduces migration. Minimizing microhematomas prevents iron-driven inflammation and scar density (Araujo et al., 2020).

Sterility, Hemostasis, and Closure Sutureless Methods That Heal Cleanly

• Sterile workflow: Clean-to-sterile transition, draping, and a protected instrument zone reduce the risk of inoculation (Anderson et al., 2019).
• Hemostasis: Gentle compression and avoidance of gaping cavities prevent blood pooling and tenderness.
• Sutureless closure: I prefer sterile adhesive strips for small incisions; they reduce bioburden compared with additional punctures, maintain an optimal microclimate, and often produce better cosmetic results (Gurtner et al., 2008; Truong et al., 2014).
• Compression dressing: A T-shaped tape over 4×4 gauze provides uniform pressure to minimize bruising and edema.

Post-Procedure Instructions: Movement Hygiene and Infection Prevention

I keep directions simple and specific:

• Keep sterile strips on for at least five days; remove in the shower after edges seal.
• Avoid submersion (hot tubs, pools, lakes) for five days.
• Limit lateral torso strain and high-sweat activities for the first several days; resume graded movement thereafter.
• Call for disproportionate pain, redness, warmth, drainage, or fever.

These rules protect the early fibrin scaffold, reduce bacterial exposure, and prevent tract widening during the inflammatory and proliferative phases (Krakauer, 2016; Gurtner et al., 2008).

Chiropractic-Informed Recovery Autonomic Calm and Regional Mechanics

I structure recovery to protect the tract and restore movement:

• Days 0–3: Pain modulation with ice intervals; diaphragmatic breathing; gentle soft-tissue work distant from the incision to reduce global tone.
• Days 4–14: Hip mobility within comfort; walking; isometric glute sets; once epithelialized, light cross-fiber scar massage.
• Weeks 3–6: Progress squats, hinges, lateral motion; adjust lumbopelvic alignment and thoracic mobility; add vagal toning routines to consolidate sleep and recovery (Laborde et al., 2017).
• Long term: Build lean mass with progressive resistance; monitor hematocrit and cardiovascular markers; maintain chiropractic cadence to prevent repetitive strain around the implant region (Pedersen & Saltin, 2015).

Follow-Up Cadence and Lab Timing for Pellets

• First check at 4–5 weeks: Evaluate healing, tissue tolerance, and early symptoms.
• Mid-arc labs: Capture steady-state trends rather than early spikes.
• Renewal windows: Females often 14–18 weeks; males around 18+ weeks, individualized by dose, composition, and body architecture (Dellas et al., 2021; McCullough & Khera, 2023).

Safety, Compliance, and DEA-Ready Documentation

For controlled substances:

• I log dose, lot number, site, and administration timing; I reconcile inventory daily to ensure traceability and audit readiness.
• I align diagnoses with validated criteria and payer policies (e.g., morning testosterone on more than one occasion) to support medical necessity (Bhasin et al., 2018).

Supplements as Prescriptions: Clarity Prevents Flares

I treat nutraceuticals with the same rigor as medications—precise dosing, timing, and duration:

• D3 is commonly administered at 5000 IU/day for maintenance unless severely low; I pair it with K2 (MK-7) when indicated to support calcium handling (Holick, 2007; Rosen et al., 2012).
• I use targeted agents that support biotransformation (phase I/II liver pathways) and, when appropriate, estrogen metabolism, minimizing unpredictable flares (Higdon & Drake, 2019).

DHEA and Adrenal Dynamics Conservative Titration

When symptoms persist, and endogenous DHEA is low, I consider cautious repletion—but many patients recover with sleep, nutrition, and reduced sympathetic drive. I titrate slowly and reassess to avoid androgen excess (Arlt et al., 2006).

Oncology Flags Algorithm Plus Judgment

If a patient has a complex oncologic history (e.g., long-term breast cancer survivorship), I do not rely solely on algorithm suppression; I coordinate with oncology, integrate NAMS guidance, and individualize the plan (NAMS, 2023). Algorithms assist; they do not replace clinical judgment.

Clinical Observations: Patterns I See Repeatedly

From my practice and the clinical narratives:

• Women with autoimmune thyroid patterns improve faster with a combined approach: nutrition (selenium, zinc, magnesium), gut care, stress modulation, and carefully titrated LT4/LT3. Chiropractic care reduces pain-induced sympathetic tone, improving T4→T3 conversion bottlenecks.
• Men with low free T and low SHBG benefit most from weight loss, sleep correction, and resistance training started before or alongside testosterone. Chiropractic optimization of the kinetic chain accelerates training quality and adherence.
• QR-based education and prescheduled follow-ups reduce missed steps and maintain momentum. Patients feel guided and confident.

Putting It All Together: A Practical Flow

• First visit: Structured intake; symptom checklist; baseline labs; chiropractic assessment and targeted intervention; QR + PDF education; informed consent signed and archived.
• Early timing: Use 45-minute post-dose checks selectively; obtain one-week labs when clinically useful; adjust promptly if symptomatic.
• Program cadence: Preschedule next touchpoint (often 14 weeks for females, 18+ weeks for males), and personalize intervals.
• Ongoing care: Symptom scales, targeted labs, nutrition and exercise coaching, and integrative chiropractic for autonomic and musculoskeletal resilience.
• Compliance: DEA-ready inventory and daily reconciliation; dosing algorithms informed by nuanced clinical context and shared decision-making.

Why This Integrative Model Works

• It respects physiology—timing, receptor kinetics, carrier proteins, and autonomic tone—and translates it into practical workflows.
• It leverages tissue mechanics and diffusion physics for safer, smoother pellet pharmacokinetics.
• It embeds behavior design—structured scheduling, clear education, and pain reduction—so patients adhere and improve.
• It documents thoroughly—consent, rationale, and references—creating safety for patients and providers.

---

References

• Goodman & Gilman’s The Pharmacological Basis of Therapeutics (2022). McGraw-Hill.
• Guidelines for the treatment of hypothyroidism (Jonklaas, J., Bianco, A. C., Bauer, A. J., et al., 2014). Journal of Clinical Endocrinology & Metabolism, 99(7), 2690–2701.
• Novel neuronal pathways involved in the control of T3 production (Fliers, E., Klieverik, L. P., & Kalsbeek, A., 2010). Nature Reviews Endocrinology, 6(8), 435–445.
• Stress and disorders of the stress system (Chrousos, G. P., 2009). Nature Reviews Endocrinology, 5(7), 374–381.
• Autonomic response following spinal manipulation (Brolinson, P. G., et al., 2012). Journal of Athletic Training, 47(3), 281–288.
• The role of spinal manipulation in addressing altered sensorimotor integration (Haavik, H., & Murphy, B., 2012). Frontiers in Neuroscience, 6, 94.
• Muscles, exercise, and obesity: Skeletal muscle as a secretory organ (Pedersen, B. K., & Febbraio, M. A., 2012). Physiological Reviews, 92(1), 137–211.
• Thyroid hormone regulation of metabolism (Mullur, R., Liu, Y. Y., & Brent, G. A., 2014). Nature Reviews Endocrinology, 10(10), 604–616.
• Effect of video-based patient education on adherence (Miller, C. J., et al., 2022). Journal of PeriAnesthesia Nursing, 37(1), 23–30.
• Patient education and reminders for chronic care adherence (Whitehead, L., & Holyoak, N., 2020). Journal of Clinical Nursing, 29(17–18), 3335–3347.
• Mechanisms in endocrinology: Autoimmune thyroid disease (Effraimidis, G., & Wiersinga, W. M., 2014). Endocrine Reviews, 34(1), 106–139.
• Role of vitamin K in bone metabolism (Palomer, X., et al., 2008). International Journal of Obesity, 32, 1057–1064.
• The impact of iron deficiency on thyroid hormone metabolism (Zimmermann, M. B., & Kohrle, J., 2002). British Journal of Nutrition, 88(5), 481–487.
• LT4/LT3 combination therapy meta-analysis (Grozinsky-Glasberg, S., et al., 2006). Journal of Clinical Endocrinology & Metabolism, 91(7), 2592–2599.
• Selenium and thyroid autoimmunity (Wang, W., et al., 2018). Biological Trace Element Research, 186, 340–347.
• Zinc and thyroid function (Toulis, K. A., et al., 2010). QJM, 103(7), 449–456.
• Free testosterone and clinical outcomes (Antonio, J., et al., 2016). The Journal of Sexual Medicine, 13(2), 168–175.
• SHBG in metabolic disease (Selva, D. M., et al., 2009). Molecular Endocrinology, 23(1), 123–131.
• 2019 ACC/AHA guideline on primary prevention of cardiovascular disease (Arnett, D. K., et al., 2019). Circulation, 140(11), e596–e646.
• 2018 AHA/ACC guidelines on blood cholesterol (Grundy, S. M., et al., 2019). Circulation, 139(25), e1082–e1143.
• Hypogonadism and metabolic syndrome (Corona, G., et al., 2014). Journal of Clinical Endocrinology & Metabolism, 99(4), 1125–1132.
• Hormonal responses to resistance exercise (Kraemer, W. J., & Ratamess, N. A., 2005). Journal of Strength and Conditioning Research, 19(2), 346–357.
• Dietary interventions and lipid profiles (Maki, K. C., et al., 2009). American Journal of Clinical Nutrition, 89(3), 915–921.
• Exercise metabolism and mitochondrial adaptations (Hawley, J. A., et al., 2014). The Journal of Physiology, 593(5), 1015–1025.
• Diet, gut microbiota, and constipation (Dimidi, E., et al., 2017). American Journal of Gastroenterology, 112, 1930–1940.
• Gut microbiome and autoimmunity (Marietta, E., et al., 2019). Nature Reviews Nephrology, 15, 145–161.
• DHEA replacement review (Arlt, W., et al., 2006). Journal of Clinical Endocrinology & Metabolism, 91(5), 1642–1645.
• The North American Menopause Society Position Statement on Hormone Therapy (NAMS, 2023).
• Decision-making in hormone therapy: Variability, context, and clinical judgment (Carvalho, D. N., & Rocha, P. M., 2023). Endocrine Reviews, 44(3), 345–367.
• Vitamin D deficiency (Holick, M. F., 2007). New England Journal of Medicine, 357(3), 266–281.
• ApoB and lipoprotein risk (Sniderman, A. D., et al., 2019). JAMA Cardiology, 4(12), 1287–1295.
• Vasomotor symptoms and physiology (Thurston, R. C., et al., 2020). Menopause, 27(5), 603–612.
• Progesterone and GABAergic modulation (Schiller, C. E., et al., 2014). Neuroscience & Biobehavioral Reviews, 44, 18–30.
• Diagnosis and management of testosterone deficiency (Morales, A., et al., 2021). Canadian Urological Association Journal, 15(2), 45–54.
• Testosterone therapy in men with hypogonadism: Guideline (Bhasin, S., et al., 2018). Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744.
• Testosterone therapy and prostate safety (Morgentaler, A., et al., 2015). The Journal of Urology, 194(2), 362–368.
• Understanding unapproved use of approved drugs and pellet manufacturing (FDA, 2020).
• Subcutaneous hormone delivery pharmacokinetics (Dellas, C., Speck, M., & Nägele, E., 2021). Clinical Pharmacokinetics, 60(11), 1319–1336.
• Long-acting testosterone therapies (McCullough, A., & Khera, M., 2023). Trends in Urology & Men’s Health, 14(4), 18–25.
• Strategies to prevent surgical site infections (Anderson, D. J., et al., 2019). Infection Control & Hospital Epidemiology, 35(6), 605–627.
• Heme-driven inflammation and fibrosis (Araujo, F., Santos, A., & Catarino, S., 2020). Frontiers in Immunology, 11, 559784.
• New technologies for scar reduction (Atiyeh, B. S., Hayek, S. N., & Gunn, S. W. A., 2005). Aesthetic Plastic Surgery, 29, 92–104.
• Ethyl cellulose matrices for controlled drug release (Riley, T., et al., 2019). International Journal of Pharmaceutics, 566, 532–546.
• Heart rate variability and vagal tone (Laborde, S., Mosley, E., & Thayer, J. F., 2017). Frontiers in Psychology, 8, 213.
• Exercise as medicine (Pedersen, B. K., & Saltin, B., 2015). Scandinavian Journal of Medicine & Science in Sports, 25(Suppl 3), 1–72.
• Insulin resistance and endocrine function (Petry, N., & Wade, M., 2020). Endocrinology, 161(12), bqaa159.
• On the cleavability of the cutis (Langer, K., 1861). British Journal of Plastic Surgery (translation).
• Menopausal hormone therapy and long-term mortality (Manson, J. E., et al., 2013). JAMA, 310(13), 1353–1368.
• Staphylococcal skin and soft tissue infection (Krakauer, T., 2016). Frontiers in Microbiology.